Tideglusib
- Generic Name
- Tideglusib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14N2O2S
- CAS Number
- 865854-05-3
- Unique Ingredient Identifier
- Q747Y6TT42
- Background
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
- Indication
Tideglusib was initially formulated for the treatment of Alzheimer and progressive supranuclear palsy. The raising interest for the use of tideglusib comes from the significant upregulation of GSK-3 in the brain in patients with Alzheimer disease. Its function as a degradant of β-catenin, was also important, as it prevents the transcription of cell survival genes. All these factors have directed current research towards this kinase as a potential target. Alzheimer disease is the most prevalent form of dementia. The most accepted hypothesis to explain this disease is related to the presence of amyloid β, which triggers a cascade that will alter the Tau protein and provoke synaptic dysfunction and neuronal death.
GSK-3 importance in the tissue repair pathway has also pointed out a novel application for tideglusib. Thus, it is also under the research for the natural repair treatment of deep caries lesions.
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
- Conditions
- Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06174220
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 98
- Registration Number
- NCT05105958
- Locations
- 🇨🇭
University Hospital Lausanne, Lausanne, Switzerland
🇨🇭University Hospital Zurich, Zürich, Switzerland
🇨🇭University Hospital Bern, Bern, Switzerland
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 76
- Registration Number
- NCT05004129
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇳🇿New Zealand Clinical Research (NZCR), Auckland, New Zealand
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 56
- Registration Number
- NCT03692312
- Locations
- 🇦🇺
The Bright Alliance, Randwick, New South Wales, Australia
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
🇳🇿New Zealand Clinical Research (NZCR), Auckland, New Zealand
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 16
- Registration Number
- NCT02858908
- Locations
- 🇬🇧
Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- Evdokia Anagnostou
- Target Recruit Count
- 83
- Registration Number
- NCT02586935
- Locations
- 🇨🇦
McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada
🇨🇦University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada
🇨🇦Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Noscira SA
- Target Recruit Count
- 306
- Registration Number
- NCT01350362
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Drug: placebo
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Noscira SA
- Target Recruit Count
- 146
- Registration Number
- NCT01049399
- Locations
- 🇺🇸
University of Medicine and Dentistry, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇪🇸Fundació Ace, Barcelona, Spain
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Noscira SA
- Target Recruit Count
- 30
- Registration Number
- NCT00948259
- Locations
- 🇩🇪
Pharmacologische Studiecentrum Chemnitz, Chemnitz, Germany
🇩🇪Studienzentrum PD Dr. Steinwachs, Nürnberg, Germany
🇩🇪Arzneimittelforschung Leipzig GmbH, Leipzig, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.